255 related articles for article (PubMed ID: 33048878)
1. Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy.
Sibiude J; Le Chenadec J; Mandelbrot L; Dollfus C; Matheron S; Lelong N; Avettand-Fenoel V; Brossard M; Frange P; Reliquet V; Warszawski J; Tubiana R;
AIDS; 2021 Feb; 35(2):219-226. PubMed ID: 33048878
[TBL] [Abstract][Full Text] [Related]
2. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
Chouchana L; Beeker N; Treluyer JM
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Patel K; Huo Y; Jao J; Powis KM; Williams PL; Kacanek D; Yee LM; Chadwick EG; Shiau S; Jacobson DL; Brummel SS; Sultan-Beyer L; Kahlert CR; Zash R; Seage GR; ;
N Engl J Med; 2022 Sep; 387(9):799-809. PubMed ID: 36053505
[TBL] [Abstract][Full Text] [Related]
4. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
[TBL] [Abstract][Full Text] [Related]
5. Adverse drug reactions to integrase strand transfer inhibitors.
Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
[TBL] [Abstract][Full Text] [Related]
6. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.
Zash R; Holmes L; Diseko M; Jacobson DL; Brummel S; Mayondi G; Isaacson A; Davey S; Mabuta J; Mmalane M; Gaolathe T; Essex M; Lockman S; Makhema J; Shapiro RL
N Engl J Med; 2019 Aug; 381(9):827-840. PubMed ID: 31329379
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
Pereira GFM; Kim A; Jalil EM; Fernandes Fonseca F; Shepherd BE; Veloso VG; Rick F; Ribeiro R; Pimenta MC; Beber A; Corrêa RG; Lima R; Maruri F; McGowan CC; Schwartz Benzaken A; Grinsztejn B; Castilho JL;
Lancet HIV; 2021 Jan; 8(1):e33-e41. PubMed ID: 33387477
[TBL] [Abstract][Full Text] [Related]
8. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort.
Cuzin L; Pugliese P; Katlama C; Bani-Sadr F; Ferry T; Rey D; Lourenco J; Bregigeon S; Allavena C; Reynes J; Cabié A;
J Antimicrob Chemother; 2019 Mar; 74(3):754-760. PubMed ID: 30534993
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
Nguyen B; Foisy MM; Hughes CA
Ann Pharmacother; 2019 Aug; 53(8):833-844. PubMed ID: 30739498
[No Abstract] [Full Text] [Related]
10. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
Llibre JM; Montoliu A; Miró JM; Domingo P; Riera M; Tiraboschi J; Curran A; Homar F; Ambrosioni J; Abdulghani N; Force L; Peraire J; Casabona J;
HIV Med; 2019 Mar; 20(3):237-247. PubMed ID: 30688007
[TBL] [Abstract][Full Text] [Related]
11. Tolerability of integrase inhibitors in a real-life setting.
Peñafiel J; de Lazzari E; Padilla M; Rojas J; Gonzalez-Cordon A; Blanco JL; Blanch J; Marcos MA; Lonca M; Martinez-Rebollar M; Laguno M; Tricas A; Rodriguez A; Mallolas J; Gatell JM; Martinez E
J Antimicrob Chemother; 2017 Jun; 72(6):1752-1759. PubMed ID: 28333231
[TBL] [Abstract][Full Text] [Related]
12. Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
Rolle CP; Castano J; Nguyen V; Patel K; Hinestrosa F; DeJesus E
Antivir Ther; 2023 Feb; 28(2):13596535231163703. PubMed ID: 36896821
[TBL] [Abstract][Full Text] [Related]
13. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
[TBL] [Abstract][Full Text] [Related]
15. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
16. Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV.
O'Halloran JA; Wang K; Spence AB; Williams DW; Dastgheyb R; Fitzgerald KC; Kamkwalala AR; Maki PM; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Lahiri CD; Sheth AN; Xu Y; Rubin LH
J Acquir Immune Defic Syndr; 2021 Apr; 86(5):593-599. PubMed ID: 33394812
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir Neuropsychiatric Adverse Events: Specific Drug Effect or Class Effect.
Yombi JC
AIDS Rev; 2018; 20(1):14-26. PubMed ID: 29628511
[TBL] [Abstract][Full Text] [Related]
18. HIV pharmacotherapy: A review of integrase inhibitors.
Wong E; Trustman N; Yalong A
JAAPA; 2016 Feb; 29(2):36-40. PubMed ID: 26818644
[TBL] [Abstract][Full Text] [Related]
19. Integrase Strand Transfer Inhibitor Use in Children with Perinatal HIV-1 Infection: A Narrative Review.
Failla M; Pasquali E; Galli L; Chiappini E
AIDS Res Hum Retroviruses; 2023 Jun; 39(6):263-284. PubMed ID: 36352827
[TBL] [Abstract][Full Text] [Related]
20. Tolerability of HIV integrase inhibitors.
Lee FJ; Carr A
Curr Opin HIV AIDS; 2012 Sep; 7(5):422-8. PubMed ID: 22886031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]